journal article·2024-12Open access

Bimetallic clusterzymes-loaded dendritic mesoporous silica particle regulate arthritis microenvironment via ROS scavenging and YAP1 stabilization

Yang Jin, Chuan Hu, Jiechao Xia, Dingqi Xie, Lin Ye, Xinyi Ye, Li Jiang, Honghai Song, Yutao Zhu, Sicheng Jiang, Weiqing Li, Weiming Qi, Yannan Yang, Zhijun Hu

Abstract

Clusterzymes are synthetic enzymes exhibiting substantial catalytic activity and selectivity, which are uniquely driven by single-atom constructs. A dramatic increase in antioxidant capacity, 158 times more than natural trolox, is noted when single-atom copper is incorporated into gold-based clusterzymes to form Au 24 Cu 1 . Considering the inflammatory and mildly acidic microenvironment characteristic of osteoarthritis (OA), pH-dependent dendritic mesoporous silica nanoparticles (DMSNs) coupled with PEG have been employed as a delivery system for the spatial-temporal release of clusterzymes within active articular regions, thereby enhancing the duration of effectiveness. Nonetheless, achieving high therapeutic efficacy remains a significant challenge. Herein, we describe the construction of a Clusterzymes-DMSNs-PEG complex (CDP) which remarkably diminishes reactive oxygen species (ROS) and stabilizes the chondroprotective protein YAP by inhibiting the Hippo pathway. In the rabbit ACLT (anterior cruciate ligament transection) model, the CDP complex demonstrated inhibition of matrix metalloproteinase activity, preservation of type II collagen and aggregation protein secretion, thus prolonging the clusterzymes' protective influence on joint cartilage structure. Our research underscores the efficacy of the CDP complex in ROS-scavenging, enabled by the release of clusterzymes in response to an inflammatory and slightly acidic environment, leading to the obstruction of the Hippo pathway and downstream NF-κB signaling pathway. This study illuminates the design, composition, and use of DMSNs and clusterzymes in biomedicine, thus charting a promising course for the development of novel therapeutic strategies in alleviating OA. • The pore loading clusterzyme of DMSNs was utilized to achieve responsive release in arthritis. • The CDP show excellent biocompatibility and bioactivity, with no adverse reactions observed in animal models. • CDP facilitated ROS scavenging and Hippo pathway inhibition processes by providing bioactive enzyme substances. • The long-term cartilage protection of rabbit ACLT model was achieved by injecting CDP nanoparticles.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced biosensing and bioanalysis techniques · Extracellular vesicles in disease · Protease and Inhibitor Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (63)

Show source-provided references
1. Risk of metabolic abnormalities in osteoarthritis: a new perspective to understand its pathological mechanisms10.1038/s41413-023-00301-9 ↗
2. Epidemiology of osteoarthritis10.1016/j.cger.2010.03.001 ↗
3. Osteoarthritis year in review 2021: epidemiology & therapy10.1016/j.joca.2021.10.003 ↗
4. Type X collagen synthesis in human osteoarthritic cartilage. Indication of chondrocyte hypertrophy10.1002/art.1780350715 ↗
5. Expression of early and late differentiation markers (proliferating cell nuclear antigen, syndecan-3, annexin VI, and alkaline phosphatase) by human osteoarthritic chondrocytes10.1016/S0002-9440(10)63024-6 ↗
6. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes10.1016/S1471-4906(02)02302-5 ↗
7. Osteochondral scaffolds for early treatment of cartilage defects in osteoarthritic joints: from bench to clinic
8. Additive manufactured polyether-ether-ketone implants for orthopaedic applications: a narrative review
9. Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes10.1039/c3cs35486e ↗
10. An artificial metalloenzyme with the kinetics of native enzymes10.1126/science.aah4427 ↗
11. Nanozymes: from new concepts, mechanisms, and standards to applications10.1021/acs.accounts.9b00140 ↗
12. Atomic engineering of clusterzyme for relieving acute neuroinflammation through lattice expansion10.1021/acs.nanolett.0c05148 ↗
13. Catalytically potent and selective clusterzymes for modulation of neuroinflammation through single-atom substitutions10.1038/s41467-020-20275-0 ↗
14. Nano-gold as artificial enzymes: hidden talents10.1002/adma.201400238 ↗
15. Regulation of synovial macrophages polarization by mimicking efferocytosis for therapy of osteoarthritis10.1002/adfm.202207637 ↗
16. Biphase stratification approach to three-dimensional dendritic biodegradable mesoporous silica nanospheres10.1021/nl404316v ↗
17. Anion assisted synthesis of large pore hollow dendritic mesoporous organosilica nanoparticles: understanding the composition gradient10.1021/acs.chemmater.5b03963 ↗
18. Glutathione-depletion mesoporous organosilica nanoparticles as a self-adjuvant and Co-delivery platform for enhanced cancer immunotherapy10.1016/j.biomaterials.2018.05.025 ↗
19. Dendritic mesoporous nanoparticles: structure, synthesis and properties10.1002/anie.202112752 ↗
20. pH-responsive core–shell structured nanoparticles for triple-stage targeted delivery of doxorubicin to tumors10.1021/acsami.6b07173 ↗
21. Intra-articular nanodrug delivery strategies for treating osteoarthritis10.1016/j.drudis.2022.103482 ↗
22. A pH-responsive cluster metal-organic framework nanoparticle for enhanced tumor accumulation and antitumor effect
23. A metal-phenolic nanosensitizer performs hydrogen sulfide-reprogrammed oxygen metabolism for cancer radiotherapy intensification and immunogenicity10.1002/anie.202200830 ↗
24. ROS-responsive berberine polymeric micelles effectively suppressed the inflammation of rheumatoid arthritis by targeting mitochondria10.1007/s40820-020-0410-x ↗
25. Dendritic mesoporous silica nanoparticles for pH-stimuli-responsive drug delivery of TNF-alpha10.1002/adhm.201700012 ↗
26. Osteoporosis remission and new bone formation with mesoporous silica nanoparticles10.1002/advs.202101107 ↗
27. Icosahedral crown gold nanocluster Au43Cu12 with high catalytic activity10.1021/nl100017u ↗
28. Atomically tailored gold nanoclusters for catalytic application10.1002/ange.201814156 ↗
29. Tumor-selective catalytic nanomedicine by nanocatalyst delivery10.1038/s41467-017-00424-8 ↗
30. ROS‐Responsive camptothecin prodrug nanoparticles for on‐demand drug release and combination of chemotherapy and photodynamic therapy10.1002/adfm.202005918 ↗
31. Crystal structure of the gold nanoparticle [N(C8H17)4][Au25(SCH2CH2Ph)18]
32. Efficient iterative schemes for ab initio total-energy calculations using a plane-wave basis set10.1103/PhysRevB.54.11169 ↗
33. Nature and strength of M-S Bonds (M) Au, Ag, and Cu) in binary alloy gold clusters10.1021/jp100423b ↗
34. Reactive oxygen species, aging and articular cartilage homeostasis10.1016/j.freeradbiomed.2018.08.038 ↗
35. Fe-curcumin nanozyme-mediated reactive oxygen species scavenging and anti-inflammation for acute lung injury10.1021/acscentsci.1c00866 ↗
36. Osteoarthritis: pathogenic signaling pathways and therapeutic targets10.1038/s41392-023-01330-w ↗
37. Interactions between Sox9 and ␤-catenin control chondrocyte differentiation10.1101/gad.1171104 ↗
38. Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases10.1016/j.xcrm.2022.100881 ↗
39. ROS/oxidative stress signaling in osteoarthritis10.1016/j.bbadis.2016.01.003 ↗
40. Oxidative stress-CBP axis modulates MOB1 acetylation and activates the Hippo signaling pathway10.1093/nar/gkac189 ↗
41. Hnrnpk protects against osteoarthritis through targeting WWC1 mRNA and inhibiting Hippo signaling pathway10.1016/j.ymthe.2024.02.027 ↗
42. The roles of the Hippo-YAP signalling pathway in Cartilage and Osteoarthritis10.1016/j.arr.2023.102015 ↗
43. Up-regulation of FOXD1 by YAP alleviates senescence and osteoarthritis10.1371/journal.pbio.3000201 ↗
44. Reciprocal inhibition of YAP/TAZ and NF-kappaB regulates osteoarthritic cartilage degradation10.1038/s41467-018-07022-2 ↗
45. Excavating bioactivities of nanozyme to remodel microenvironment for protecting chondrocytes and delaying osteoarthritis
46. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis10.1038/nrrheum.2016.136 ↗
47. Redox and NF-κB signaling in osteoarthritis10.1016/j.freeradbiomed.2018.09.025 ↗
48. The NF-κB signalling pathway in osteoarthritis10.1016/j.biocel.2013.08.018 ↗
49. Dendrobine alleviates cellular senescence and osteoarthritis via the ROS/NF-κB Axis10.3390/ijms24032365 ↗
50. Identification of the receptor component of the IkappaBalpha-ubiquitin ligase10.1038/25159 ↗
51. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro10.1101/gad.13.3.270 ↗
52. Signal-induced ubiquitination of IκBα by the F-box protein Slimb/␤-TrCP10.1101/gad.13.3.284 ↗
53. Early changes in osteochondral tissues in a rabbit model of post‐traumatic osteoarthritis10.1002/jor.25009 ↗
54. Anterior cruciate ligament rupture and osteoarthritis progression10.2174/1874325001206010295 ↗
55. Maintaining hypoxia environment of subchondral bone alleviates osteoarthritis progression
56. Osteoarthritis animal models for biomaterial-assisted osteochondral regeneration
57. State of the Art: imaging of osteoarthritis—Revisited 202010.1148/radiol.2020192498 ↗
58. The OARSI histopathology initiative – recommendations for histological assessments of osteoarthritis in the rabbit10.1016/j.joca.2010.05.029 ↗
59. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints10.1172/JCI119526 ↗
60. Posttraumatic osteoarthritis after athletic knee injury: a narrative review of diagnostic imaging strategies10.1002/pmrj.13217 ↗
61. Two-stage Classification of future knee osteoarthritis severity after 8 Years using MRI: data from the osteoarthritis initiative10.1007/s10439-024-03578-x ↗
62. Oxidative stress, autophagy, epigenetic changes and regulation by miRNAs as potential therapeutic targets in osteoarthritis10.1016/j.bcp.2015.12.012 ↗
63. Osteocyte dysfunction promotes osteoarthritis through MMP13-dependent suppression of subchondral bone homeostasis10.1038/s41413-019-0070-y ↗